Effect of Resmetirom, a Selective Thyroid Hormone Receptor Beta Agonist, On Hepatic Hypothyroidism in a 52-Week Non-Cirrhotic NASH Phase 3 Clinical Trial
Thursday, May 12, 2022
1:50 PM – 2:10 PM
Location: Learning Lab B - AACE Learning Zone
Submitter(s)
Kathryn Jean Lucas, MD
Principal Investigator Lucas Research, Inc. Morehead City, North Carolina, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
